Compare Alibaba Group (BABA) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Gilead Sciences, Inc. — how do they compare? Alibaba Group trades at $117.27 (market cap $270.95B), while Gilead Sciences, Inc. trades at $129.81 (market cap $161.45B). The key difference: Alibaba Group is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.52%). Which is the better fit depends on your goals.
| BABA | GILD | |
|---|---|---|
Market Cap | $270.95B | $161.45B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $155.80 |
52-Week Low | $94.83 | $108.22 |
Enterprise Value | $265.77B | $175.98B |
Dividend Yield | 0.93% | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $112.35, up 0.02% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings misses contrast with robust fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 17.36 appear reasonable. The stock faces headwinds from securities investigations but benefits from AI-driven optimism in cloud growth.
Outlook remains positive given Wall Street's $195 price target and 86% buy ratings, though risks include legal overhangs and earnings volatility. AI and cloud initiatives offer growth catalysts, but investors should monitor regulatory developments and quarterly execution against expectations.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
